comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 00:29:37 - browse：92292

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Cord blood banking comes at a high cost to babies

focus

hotspot

WSS

Woman returns to dialysis after doctors remove transplanted pig kidney

Woman returns to dialysis after doctors remove transplanted pig kidney

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

H.R. 3 is the wrong path to lower drug costs

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

hotspot

comprehensive

focus

New air purifier tech could be key to improving indoor air quality

Cord blood banking comes at a high cost to babies

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

See how much Covid

Anesthesiologist group: stop taking Ozempic before surgery

Group behind ProMed defends move to subscription

Trump demands the U.S. pay no more for drugs than other countries … again

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

BioMarin wins approval for gene therapy to treat hemophilia A

Chris Christie meets with Zelenskyy during Ukraine trip

explore

FDA approves Sage Therapeutics’ rapid

How I helped Pfizer think through the ethics of Viagra

Ionis drug prevents swelling attacks due to hereditary angioedema

Letters to First Opinion on caregivers, digital health, and more

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

ASCO: Palliative care found as helpful given virtually as in person

focus

focus

hotspot

Wikipedia